Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus MINTEZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus MINTEZOL.
EMVERM vs MINTEZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Category C
Category C
Anthelmintic
Anthelmintic